COX-2 Inhibition in Schizophrenia and Major Depression
The DOI matches its Crossref record.
Abstract
In schizophrenia and depression, opposite patterns of type-1 - type-2 immune response seem to be associated with differences in the activation of the enzyme indoleamine 2,3-dioxygenase (IDO) and in the tryptophan - kynurenine metabolism resulting in increased production of kynurenic acid in schizophrenia and decreased production of kynurenic acid in depression. These differences are associated with an imbalance in the glutamatergic neurotransmission, which may contribute to an overweight of N-methyl-D-aspartate (NMDA) agonism in depression and of NMDA antagonism in schizophrenia. The differential activation of microglia cells and astrocytes may be an additional mechanism contributing to this imbalance. The immunological imbalance results both in schizophrenia and in depression in an increased Prostaglandin E(2) (PGE(2)) production and probably also in an increased Cyclo-oxygenase-2 (COX-2) expression. Although there is strong evidence for the view, that the interactions of the immune system, IDO, the serotonergic system, and the glutamatergic neurotransmission play a key role in schizophrenia and in depression, several gaps, e.g. the roles of genetics, disease course, sex, different psychopathological states, etc. have to be bridged by intense further research. There are already hints that anti-inflammatory therapy may have beneficial effects in schizophrenia and major depression. COX-2 inhibititors have been tested in animal models of depression and in preliminary clinical trials, the latter showing favourable effects compared to placebo, both, in schizophrenia and in major depression. The effects of COX-2 inhibition in the central nervous system (CNS) as well as the different components of the inflammatory system, the kynurenine-metabolism and the glutamatergic neurotransmission, however, still need careful further validation including clinical studies with sufficient sample size.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
A Starring Role for Microglia in Brain Sex Differences
Lenz, K. M., & McCarthy, M. M. (2015) · The Neuroscientist · doi:10.1177/1073858414536468 · Cited by 342
The Impact of Systemic Inflammation on Neurodevelopment
Jiang, N. M., Cowan, M., Moonah, S. N., & Petri, W. A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.008 · Cited by 328
Meyer, U., Schwarz, M. J., & Müller, N. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.003 · Cited by 258
Self-citationLoftis, J. M., Huckans, M., & Morasco, B. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.015 · Cited by 252
Metadata
- Authors
- Muller, N., & Schwarz, M.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-05-01
- Volume
- 14
- Issue
- 14
- Pages
- 1452-1465
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2068144727
- Cited by
- 101
- References
- 0
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COX-2 Inhibition in Schizophrenia and Major Depression. https://app.cochat.ai/papers/10.2174/138161208784480243
- The paper
- Muller, N., & Schwarz, M. (2008). COX-2 Inhibition in Schizophrenia and Major Depression. Current Pharmaceutical Design. https://doi.org/10.2174/138161208784480243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.